We are proud to share that our founder and chief product officer at Wemedoo has been elected as a senior expert in drug development with expertise in Artificial Intelligence by the EUCROF AI Expert Group.
This nomination reflects Dr. Cihoric’s long dedication to advancing digital changes in healthcare and his unique ability to bridge medical science with AI-driven technological innovation.
The EUCROF AI Expert Group unites experts to define how AI is applied in clinical research, an effort Dr. Cihoric supported at the EU Commission’s AI meeting.
His election into this expert body further validates Wemedoo’s vision of building a smarter future for drug development where technology is not just a support tool but a key factor of quality, speed, and patient-centered progress.
Wemedoo thanks to the EUCROF team for their support and transparent collaboration through this process.
The next Full Members’ Board (FMB) meeting is scheduled for Wednesday, 23 July (11:00–13:00 CEST).
February 27, 2025
Across Global Alliance Selects Wemedoo’s oomnia® as Central Clinical Trial Infrastructure
Company News
October 2, 2024
Interview with Dr. Nikola Čihorić: The Role of Common Data Elements in Breast Cancer Care
Company News
May 7, 2025
New Era of Clinical Trials with oomnia®: Built for Complexity, Designed for Simplicity
Company News